Navigation Links
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Date:5/6/2008

Milestone Payments slated for reduction from $25 Million to $7 Million,

Royalties from 10-12% to 4%

HOPKINTON, Mass., May 6 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Company's Cethrin License Agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Pursuant to the option agreement, the pre-commercial milestone payments in the amended license agreement will be reduced from $25 million to $7 million payable on or before December 31, 2009. In addition, the sales-based royalties in the amended license agreement will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications. Finally, the amended license agreement will eliminate all development milestones related to Cethrin.

"This agreement represents a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform," stated Peter Savas, Chairman and Chief Executive Officer. "Our strategy for our spinal cord injury program and our other regenerative therapeutics is to demonstrate efficacy in humans and then seek attractive partnerships for the assets. In addition to reducing the future cash burdens of the license, we believe that the reduction in our future royalty obligations will allow us to more freely explore worldwide collaboration and partnership opportunities not only in spinal cord injury b
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... identified an important cancer gene that could lead to more ... a disease which currently has a poor prognosis. The ... was one of a number of significant genetic differences found ... are the most common brain tumour in children. Clinicians ...
... Up-to-Date ... , ... NJ (PRWEB) May 18, 2010 -- Projects In Knowledge ( www.projectsinknowledge.com ), a fully ... approved iPhone application developer. The company has just launched Living Medical Textbook Neurology: Multiple ...
... adds to ongoing health risks , TUESDAY, May ... of smoke, dust, fumes and gases among those involved ... Trade Center ultimately compromised the workers, sense of smell, ... diminished ability to detect odors and irritants, researchers at ...
... ... ... look like two ordinary guys, and they will even tell you that’s all they are, but ... after nearly 3 months of rollerblading across the United States. With such a grueling task, they ...
... ... the news because they are becoming more popular and may even be permanent alternatives to ... the results people want. Advancements in technology and techniques are also making these treatments ... ...
... ... played a role in the 30th Annual Texas History Day Contest; albeit, one behind the ... Irving, TX ... provider of upper extremity rehabilitation services recently played a role in the 30th Annual Texas ...
Cached Medicine News:Health News:Genetics of children's brain tumor unlocked 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 2Health News:Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition 3Health News:Lost Sense of Smell Noted Among Ground Zero Workers Post-9/11 2Health News:Rollerbladers Finish Grueling Cross Country Trek Helped by Tahitian Noni Products 2Health News:Dr. Alexander Rivkin's Pioneering Non-Surgical Nose and Eye Transformations Are Making Headlines and May Be Permanent Solutions 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 2Health News:Advanced Arm Dynamics Helps Eighth Grade Students Make History 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: